{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:45:21Z","timestamp":1792601121240,"version":"4.5.0"},"reference-count":136,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, continue to challenge clinicians with complex treatment regimens that often involve significant side effects and limited success, especially in advanced stages. Recent advancements in nuclear medicine have introduced theranostic strategies that merge diagnostic imaging with targeted therapeutic approaches, offering the potential for more precise and personalized treatment. A key area of progress lies in the development of alpha-emitting radiopharmaceuticals, such as 225Ac, 211At, or 212Pb, which can deliver potent radiation directly to tumor cells, sparing healthy tissue and minimizing collateral damage. In parallel with these therapeutic advancements, molecular imaging using radiolabeled agents enables better disease monitoring, assessment of treatment efficacy, and personalized management of patients with hematologic malignancies. The integration of diagnostic imaging with radiotherapy allows for a more tailored approach, where treatment can be adjusted based on real-time information about tumor progression and response. This review examines the recent strides made in both the development of radiopharmaceuticals and their applications in molecular imaging, with a focus on the potential to improve precision, reduce toxicity, and optimize patient outcomes. The synergy between targeted therapy and molecular imaging represents a transformative shift in the management of hematologic malignancies. As these technologies evolve, they are poised to redefine treatment paradigms, offering new hope for patients and potentially improving survival rates with more effective and less toxic treatment options.<\/jats:p>","DOI":"10.3390\/cancers17071247","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:30:59Z","timestamp":1744003859000},"page":"1247","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Theranostics in Hematological Malignancies: Cutting-Edge Advances in Diagnosis and Targeted Therapy"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6074-8838","authenticated-orcid":false,"given":"Bojana","family":"Bogdanovic","sequence":"first","affiliation":[{"name":"Laboratory of Bioclinical Radiopharmaceutics, University Grenoble Alpes, INSERM, CHU Grenoble Alpes, 38000 Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1706-6917","authenticated-orcid":false,"given":"Florent","family":"Hugonnet","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Centre Hospitalier Princesse Grace, 98000 Monaco, Monaco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-1812","authenticated-orcid":false,"given":"Christopher","family":"Montemagno","sequence":"additional","affiliation":[{"name":"Laboratory of Bioclinical Radiopharmaceutics, University Grenoble Alpes, INSERM, CHU Grenoble Alpes, 38000 Grenoble, France"},{"name":"Biomedical Department, Centre Scientifique de Monaco, 98000 Monaco, Monaco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","article-title":"Diagnosis and Classification of Hematologic Malignancies on the Basis of Genetics","volume":"130","author":"Taylor","year":"2017","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global Burden of Hematologic Malignancies and Evolution Patterns over the Past 30 Years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"993915","DOI":"10.3389\/fcell.2022.993915","article-title":"Lessons to Cancer from Studies of Leukemia and Hematopoiesis","volume":"10","author":"Brown","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1328200","DOI":"10.3389\/fonc.2024.1328200","article-title":"An Efficient Decision Support System for Leukemia Identification Utilizing Nature-Inspired Deep Feature Optimization","volume":"14","author":"Awais","year":"2024","journal-title":"Front. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple Myeloma: 2024 Update on Diagnosis, Risk-Stratification, and Management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sochacka-\u0106wik\u0142a, A., M\u0105czy\u0144ski, M., and Regiec, A. (2021). FDA-Approved Drugs for Hematological Malignancies\u2014The Last Decade Review. Cancers, 14.","DOI":"10.3390\/cancers14010087"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.123.265670","article-title":"What Is Theranostics?","volume":"64","author":"Weber","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s11912-024-01526-5","article-title":"Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update","volume":"26","author":"Zanoni","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.2147\/OTT.S140671","article-title":"Theranostics in Nuclear Medicine Practice","volume":"10","author":"Yordanova","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Echavidre, W., Fagret, D., Faraggi, M., Picco, V., and Montemagno, C. (2023). Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future. Cancers, 15.","DOI":"10.3390\/cancers15194839"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14737140.2.5.485","article-title":"Zevalin: The First Radioimmunotherapy Approved for the Treatment of Lymphoma","volume":"2","year":"2002","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2967\/jnumed.107.043489","article-title":"Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice","volume":"48","author":"Jacene","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3747\/co.v16i5.385","article-title":"131I\u2013Tositumomab in Lymphoma","volume":"16","author":"Cheung","year":"2009","journal-title":"Curr. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Rituximab-Refractory Follicular Non-Hodgkin\u2019s Lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy versus Rituximab Immunotherapy for Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin\u2019s Lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Omer, M.H., Shafqat, A., Ahmad, O., Alkattan, K., Yaqinuddin, A., and Damlaj, M. (2023). Bispecific Antibodies in Hematological Malignancies: A Scoping Review. Cancers, 15.","DOI":"10.3390\/cancers15184550"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12935-024-03479-y","article-title":"Recent Updates on Allogeneic CAR-T Cells in Hematological Malignancies","volume":"24","author":"Mansoori","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.drudis.2021.11.019","article-title":"ImmunoPET Imaging of Hematological Malignancies: From Preclinical Promise to Clinical Reality","volume":"27","author":"Dun","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zamanian, M., Albano, D., Treglia, G., Rizzo, A., and Abedi, I. (2024). The Clinical Role of CXCR4-Targeted PET on Lymphoproliferative Disorders: A Systematic Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13102945"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jsps.2022.12.013","article-title":"SPECT\/CT and PET\/CT, Related Radiopharmaceuticals, and Areas of Application and Comparison","volume":"31","author":"Alqahtani","year":"2023","journal-title":"Saudi Pharm. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/1874471008666150313114644","article-title":"Theranostic Applications of Lutetium-177 in Radionuclide Therapy","volume":"9","author":"Das","year":"2016","journal-title":"Curr. Radiopharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2001879","DOI":"10.1002\/advs.202001879","article-title":"CD38-Targeted Theranostics of Lymphoma with 89Zr\/177Lu-Labeled Daratumumab","volume":"8","author":"Kang","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7597","DOI":"10.18632\/oncotarget.6531","article-title":"90 Y-Ibritumomab Tiuxetan: A Nearly Forgotten Opportunity","volume":"7","author":"Mondello","year":"2015","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2967\/jnumed.117.190124","article-title":"The Future of Radioligand Therapy: \u03b1, \u03b2, or Both?","volume":"58","author":"Haberkorn","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.7150\/thno.96403","article-title":"Actinium-225 Targeted Alpha Particle Therapy for Prostate Cancer","volume":"14","author":"Bidkar","year":"2024","journal-title":"Theranostics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00259-022-05821-w","article-title":"In Vitro Dose Effect Relationships of Actinium-225- and Lutetium-177-Labeled PSMA-I&T","volume":"49","author":"Ruigrok","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Eychenne, R., Ch\u00e9rel, M., Haddad, F., Gu\u00e9rard, F., and Gestin, J.-F. (2021). Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The \u201cHopeful Eight\u201d. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13060906"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1607673","DOI":"10.1080\/2162402X.2019.1607673","article-title":"Daratumumab-225Actinium Conjugate Demonstrates Greatly Enhanced Antitumor Activity against Experimental Multiple Myeloma Tumors","volume":"8","author":"Dawicki","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1051825","DOI":"10.3389\/fmed.2022.1051825","article-title":"Dual Targeting with 224Ra\/212Pb-Conjugates for Targeted Alpha Therapy of Disseminated Cancers: A Conceptual Approach","volume":"9","author":"Juzeniene","year":"2023","journal-title":"Front. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1158\/1538-7445.AM2022-5432","article-title":"Abstract 5432: Targeted Alpha Therapy with 212Pb-NNV003 in Treatment of NHL","volume":"82","author":"Dahle","year":"2022","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41416-021-01585-6","article-title":"Preclinical Study of 212Pb Alpha-Radioimmunotherapy Targeting CD20 in Non-Hodgkin Lymphoma","volume":"125","author":"Monteil","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.7150\/thno.92775","article-title":"Terbium Radionuclides for Theranostic Applications in Nuclear Medicine: From Atom to Bedside","volume":"14","author":"Koole","year":"2024","journal-title":"Theranostics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","article-title":"Auger Electrons for Cancer Therapy\u2014A Review","volume":"4","author":"Ku","year":"2019","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_35","first-page":"35","article-title":"Targeted Radionuclide Therapy: Practical Applications and Future Prospects","volume":"8","author":"Zukotynski","year":"2016","journal-title":"Biomark. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1165870","DOI":"10.3389\/fimmu.2023.1165870","article-title":"Failure of ALL Recognition by CAR T Cells: A Review of CD 19-Negative Relapses after Anti-CD 19 CAR-T Treatment in B-ALL","volume":"14","author":"Carmona","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"eabb3631","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-Dose Targeted Radionuclide Therapy Renders Immunologically Cold Tumors Responsive to Immune Checkpoint Blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Khazaei Monfared, Y., Heidari, P., Klempner, S.J., Mahmood, U., Parikh, A.R., Hong, T.S., Strickland, M.R., and Esfahani, S.A. (2023). DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15122761"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_40","first-page":"330","article-title":"Alpha Particles as Radiopharmaceuticals in the Treatment of Bone Metastases: Mechanism of Action of Radium-223 Chloride (Alpharadin) and Radiation","volume":"26","author":"Philippa","year":"2012","journal-title":"Oncology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2967\/jnumed.112.115170","article-title":"Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I\/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas","volume":"54","author":"Forrer","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MNM.0000000000000501","article-title":"Dosimetric Analysis of 177Lu-DOTA-Rituximab in Patients with Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma","volume":"37","author":"Yadav","year":"2016","journal-title":"Nucl. Med. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/MNM.0000000000001875","article-title":"Internal Dosimetry and Biodistribution of Indigenously Prepared 177 Lu-DOTA-Rituximab in Lymphoma and Other Hematological Malignancies Treated with Rituximab","volume":"45","author":"Edamadaka","year":"2024","journal-title":"Nucl. Med. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2967\/jnumed.122.264816","article-title":"Cure of Disseminated Human Lymphoma with [177Lu]Lu-Ofatumumab in a Preclinical Model","volume":"64","author":"Shim","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"924","DOI":"10.2967\/jnumed.122.265167","article-title":"Cure of Disseminated Human Lymphoma with [225Ac]Ac-Ofatumumab in a Preclinical Model","volume":"64","author":"Longtine","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/0118744710326742241018050220","article-title":"Preclinical Aspects of [89Zr]Zr-DFO-Rituximab: A High Potential Agent for Immuno-PET Imaging","volume":"18","author":"Rouhollahi","year":"2024","journal-title":"Curr. Radiopharm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1158\/1535-7163.MCT-21-0732","article-title":"89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFN\u03b1 Fusion Protein in a Murine B-Cell Lymphoma Model","volume":"21","author":"Zettlitz","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2967\/jnumed.122.264979","article-title":"Evaluation of Candidate Theranostics for 227Th\/89Zr Paired Radioimmunotherapy of Lymphoma","volume":"64","author":"Abou","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1097\/RLU.0000000000004378","article-title":"64 Cu-DOTA-Rituximab PET\/CT of B-Cell Non-Hodgkin Lymphoma for Imaging the CD20 Expression","volume":"48","author":"Lee","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Bobrowicz, M., Kubacz, M., Slusarczyk, A., and Winiarska, M. (2020). CD37 in B Cell Derived Tumors\u2014More than Just a Docking Point for Monoclonal Antibodies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249531"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","article-title":"Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals","volume":"21","author":"Lapalombella","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.2967\/jnumed.119.237230","article-title":"177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma","volume":"61","author":"Malenge","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2967\/jnumed.116.173922","article-title":"Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan","volume":"58","author":"Blakkisrud","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.117.195347","article-title":"Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan","volume":"59","author":"Blakkisrud","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1182\/bloodadvances.2020002583","article-title":"Phase 1\/2a Study of 177Lu-Lilotomab Satetraxetan in Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma","volume":"4","author":"Kolstad","year":"2020","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41375-019-0677-4","article-title":"The Therapeutic Effectiveness of 177Lu-Lilotomab in B-Cell Non-Hodgkin Lymphoma Involves Modulation of G2\/M Cell Cycle Arrest","volume":"34","author":"Pichard","year":"2020","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s11307-022-01731-3","article-title":"FDG PET\/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent Non-Hodgkin Lymphoma-Are We Hitting the Target?","volume":"24","author":"Blakkisrud","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e0230526","DOI":"10.1371\/journal.pone.0230526","article-title":"Targeted Alpha Therapy for Chronic Lymphocytic Leukaemia and Non-Hodgkin\u2019s Lymphoma with the Anti-CD37 Radioimmunoconjugate 212Pb-NNV003","volume":"15","author":"Maaland","year":"2020","journal-title":"PLoS ONE"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s00259-019-04417-1","article-title":"Targeting B-Cell Malignancies with the Beta-Emitting Anti-CD37 Radioimmunoconjugate 177Lu-NNV003","volume":"46","author":"Maaland","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1038\/s41598-022-10139-6","article-title":"89Zr-PET Imaging to Predict Tumor Uptake of 177Lu-NNV003 Anti-CD37 Radioimmunotherapy in Mouse Models of B Cell Lymphoma","volume":"12","author":"Giesen","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e0267543","DOI":"10.1371\/journal.pone.0267543","article-title":"Anti-CD37 Radioimmunotherapy with 177Lu-NNV003 Synergizes with the PARP Inhibitor Olaparib in Treatment of Non-Hodgkin\u2019s Lymphoma in Vitro","volume":"17","author":"Malenge","year":"2022","journal-title":"PLoS ONE"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40164-023-00454-7","article-title":"Targeting CD22 for B-Cell Hematologic Malignancies","volume":"12","author":"Xu","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/hematology.2019000018","article-title":"Mechanisms of and Approaches to Overcoming Resistance to Immunotherapy","volume":"2019","author":"Schultz","year":"2019","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2147\/DDDT.S150317","article-title":"Inotuzumab Ozogamicin: A CD22 mAb\u2013Drug Conjugate for Adult Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"12","author":"Yurkiewicz","year":"2018","journal-title":"Drug Des. Devel Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.canlet.2016.08.007","article-title":"Preclinical Evaluation of a Diabody-Based (177)Lu-Radioimmunoconjugate for CD22-Directed Radioimmunotherapy in a Non-Hodgkin Lymphoma Mouse Model","volume":"381","author":"Weber","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00259-015-3175-6","article-title":"High Treatment Efficacy by Dual Targeting of Burkitt\u2019s Lymphoma Xenografted Mice with a (177)Lu-Based CD22-Specific Radioimmunoconjugate and Rituximab","volume":"43","author":"Weber","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10428194.2023.2210710","article-title":"[211At]Astatine-Based Anti-CD22 Radioimmunotherapy For B-Cell Malignancies","volume":"64","author":"Laszlo","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-023-00813-x","article-title":"CD19\/CD22 Bispecific CAR-T Cells for MRD-Positive Adult B Cell Acute Lymphoblastic Leukemia: A Phase I Clinical Study","volume":"13","author":"Niu","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5556s","DOI":"10.1158\/1078-0432.CCR-07-1167","article-title":"CD74: A New Candidate Target for the Immunotherapy of B-Cell Neoplasms","volume":"13","author":"Stein","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood-2009-11-253203","article-title":"Milatuzumab Immunoliposomes Induce Cell Death in CLL by Promoting Accumulation of CD74 on the Surface of B Cells","volume":"116","author":"Hertlein","year":"2010","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/bloodadvances.2022008303","article-title":"Preclinical Studies Targeting CD74 with STRO-001 Antibody-Drug Conjugate in Acute Leukemia","volume":"7","author":"Le","year":"2023","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18632\/oncotarget.28341","article-title":"Targeting CD74 in B-Cell Non-Hodgkin Lymphoma with the Antibody-Drug Conjugate STRO-001","volume":"14","author":"Li","year":"2023","journal-title":"Oncotarget"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0969-8051(03)00082-9","article-title":"Experimental Therapy of Disseminated B-Cell Lymphoma Xenografts with 213Bi-Labeled Anti-CD74","volume":"30","author":"Michel","year":"2003","journal-title":"Nucl. Med. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/sj.leu.2403598","article-title":"CD33-Directed Therapy with Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Progress in Understanding Cytotoxicity and Potential Mechanisms of Drug Resistance","volume":"19","author":"Linenberger","year":"2005","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ijc.33865","article-title":"CD33-Directed Immunotherapy with Third-Generation Chimeric Antigen Receptor T Cells and Gemtuzumab Ozogamicin in Intact and CD33-Edited Acute Myeloid Leukemia and Hematopoietic Stem and Progenitor Cells","volume":"150","author":"Liu","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jcph.1730","article-title":"CD33-Targeted Therapies: Beating the Disease or Beaten to Death?","volume":"61","author":"Maakaron","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Allen, K.J.H., Jiao, R., Li, J., Beckford-Vera, D.R., and Dadachova, E. (2022). In Vitro and In Vivo Characterization of 89Zirconium-Labeled Lintuzumab Molecule. Molecules, 27.","DOI":"10.3390\/molecules27196589"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Rom\u00e3o, E., Krasniqi, A., Maes, L., Vandenbrande, C., Sterckx, Y.G.-J., Stijlemans, B., Vincke, C., Devoogdt, N., and Muyldermans, S. (2020). Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010310"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1158\/1535-7163.MCT-16-0251","article-title":"In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia","volume":"15","author":"Hagemann","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_80","first-page":"497","article-title":"Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy","volume":"35","author":"Hagemann","year":"2020","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cam4.3665","article-title":"225Ac-Labeled CD33-Targeting Antibody Reverses Resistance to Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia Models","volume":"10","author":"Garg","year":"2021","journal-title":"Cancer Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-21-3712","article-title":"Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab","volume":"28","author":"Rosenblat","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Testa, U., Pelosi, E., and Castelli, G. (2019). CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers, 11.","DOI":"10.3390\/cancers11091358"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"El Achi, H., Dupont, E., Paul, S., and Khoury, J.D. (2020). CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. Cancers, 12.","DOI":"10.3390\/cancers12113087"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1182\/bloodadvances.2019000173","article-title":"Approval of Tagraxofusp-Erzs for Blastic Plasmacytoid Dendritic Cell Neoplasm","volume":"4","author":"Pemmaraju","year":"2020","journal-title":"Blood Adv."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Zanotta, S., Galati, D., De Filippi, R., and Pinto, A. (2024). Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202401.0460.v1"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab Sunirine (IMGN632), a Novel CD123-Targeting Antibody-Drug Conjugate, in Relapsed or Refractory Acute Myeloid Leukaemia: A Phase 1\/2 Study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/s41375-022-01580-7","article-title":"Development of [211At]Astatine-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and Other CD123+ Malignancies","volume":"36","author":"Laszlo","year":"2022","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"928328","DOI":"10.3389\/fgene.2022.928328","article-title":"A Multi-Omic Approach Reveals Utility of CD45 Expression in Prognosis and Novel Target Discovery","volume":"13","author":"Ye","year":"2022","journal-title":"Front. Genet."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/JCO.23.02018","article-title":"Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed\/Refractory AML","volume":"43","author":"Gyurkocza","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41409-020-01000-3","article-title":"90Y-Labeled Anti-CD45 Antibody Allogeneic Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma","volume":"56","author":"Tuazon","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6932","DOI":"10.1158\/1078-0432.CCR-19-1567","article-title":"Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma","volume":"25","author":"Cassaday","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Prasad, V. (2024). CXCR4 Theranostics: A Potential Game Changer in Solid Tumors and Hematological Malignancies. Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum, Springer International Publishing.","DOI":"10.1007\/978-3-031-33533-4"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2018.02.020","article-title":"Role of CXCL12 and CXCR4 in the Pathogenesis of Hematological Malignancies","volume":"109","author":"Peled","year":"2018","journal-title":"Cytokine"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","article-title":"CXCR4: A Key Receptor in the Crosstalk between Tumor Cells and Their Microenvironment","volume":"107","author":"Burger","year":"2006","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","article-title":"CXCR4-Targeted Theranostics in Oncology","volume":"49","author":"Buck","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.7150\/thno.19119","article-title":"[177Lu]Pentixather: Comprehensive Preclinical Characterization of a First CXCR4-Directed Endoradiotherapeutic Agent","volume":"7","author":"Schottelius","year":"2017","journal-title":"Theranostics"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7150\/thno.101215","article-title":"CXCR4-Directed Endoradiotherapy with [177Lu]Pentixather Added to Total Body Irradiation for Myeloablative Conditioning in Patients with Relapsed\/Refractory Acute Myeloid Leukemia","volume":"15","author":"Braitsch","year":"2025","journal-title":"Theranostics"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Christensen, K.A., Fath, M.A., Ewald, J.T., Robles-Planells, C., Graves, S.A., Johnson, S.S., Zacharias, Z.R., Houtman, J.C.D., O\u2019Dorisio, M.S., and Schultz, M.K. (2024). Targeting CXCR4 with [212Pb\/203Pb]-Pentixather Significantly Increases Overall Survival in Small Cell Lung Cancer. bioRxiv.","DOI":"10.1101\/2024.09.06.611663"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood-2021-150884","article-title":"The Role of CD38 in Multiple Myeloma Cell Biology","volume":"138","author":"Kawano","year":"2021","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"15330338221106563","DOI":"10.1177\/15330338221106563","article-title":"Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison with Daratumumab","volume":"21","author":"Shen","year":"2022","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00277-023-05218-1","article-title":"Real-World Clinical Outcomes in Patients with Multiple Myeloma Treated with Isatuximab after Daratumumab Treatment","volume":"102","author":"Kikuchi","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"22486","DOI":"10.1021\/acsomega.3c00624","article-title":"89Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET Imaging of Multiple Myeloma and Lymphomas","volume":"8","author":"Michel","year":"2023","journal-title":"ACS Omega"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2967\/jnumed.124.269393","article-title":"CD38-Targeted 89Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care","volume":"66","author":"Ulaner","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1021\/acs.molpharmaceut.2c00279","article-title":"99mTc-CD3813: A Nanobody-Based Single Photon Emission Computed Tomography Radiotracer with Clinical Potential for Myeloma Imaging and Evaluation of CD38 Expression","volume":"19","author":"Shi","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1021\/acs.molpharmaceut.1c00733","article-title":"Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053","volume":"19","author":"Wei","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00259-024-07036-7","article-title":"CD38-Specific immunoPET Imaging for Multiple Myeloma Diagnosis and Therapeutic Monitoring: Preclinical and First-in-Human Studies","volume":"52","author":"Huang","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1007\/s00259-021-05218-1","article-title":"ImmunoPET Imaging of Multiple Myeloma with [68Ga]Ga-NOTA-Nb1053","volume":"48","author":"Wang","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e2308617","DOI":"10.1002\/advs.202308617","article-title":"CD38-Specific Gallium-68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET","volume":"11","author":"Sharma","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s11307-024-01901-5","article-title":"Development of New CD38 Targeted Peptides for Cancer Imaging","volume":"26","author":"Zheleznyak","year":"2024","journal-title":"Mol. Imaging Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13045-021-01171-6","article-title":"A Non-Internalised CD38-Binding Radiolabelled Single-Domain Antibody Fragment to Monitor and Treat Multiple Myeloma","volume":"14","author":"Duray","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2967\/jnumed.119.239491","article-title":"212Pb \u03b1-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study","volume":"61","author":"Quelven","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.18632\/oncotarget.2986","article-title":"\u03b1-Radioimmunotherapy with 213Bi-Anti-CD38 Immunoconjugates Is Effective in a Mouse Model of Human Multiple Myeloma","volume":"6","author":"Teiluf","year":"2015","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1182\/blood.2019001250","article-title":"The \u03b1-Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in a Disseminated Disease Model","volume":"134","author":"Comstock","year":"2019","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.120.251983","article-title":"Comparison of CD38-Targeted \u03b1- Versus \u03b2-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model","volume":"62","author":"Minnix","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"169","DOI":"10.20517\/cdr.2022.138","article-title":"Anti-BCMA Novel Therapies for Multiple Myeloma","volume":"6","author":"Sammartano","year":"2023","journal-title":"Cancer Drug Resist."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Xing, L., Liu, Y., and Liu, J. (2023). Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy. Cancers, 15.","DOI":"10.3390\/cancers15082240"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"839097","DOI":"10.3389\/fimmu.2022.839097","article-title":"Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T Cell Therapy in Multiple Myeloma: Current Status and Future Challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00259-024-06907-3","article-title":"Discovery of a Highly Specific Radiolabeled Antibody Targeting B-Cell Maturation Antigen: Applications in PET Imaging of Multiple Myeloma","volume":"52","author":"Ma","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2023-188055","article-title":"BCMA-Directed Low Dose Alpha-Emitter Therapy Eliminates Minimal Residual Disease in a Multiple Myeloma Mouse Xenograft Model","volume":"142","author":"Comstock","year":"2023","journal-title":"Blood"},{"key":"ref_124","first-page":"1637","article-title":"CS1 (SLAMF7, CD319) Is an Effective Immunotherapeutic Target for Multiple Myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"6759","DOI":"10.1158\/1078-0432.CCR-16-2870","article-title":"FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","volume":"23","author":"Gormley","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1007\/s00259-020-05097-y","article-title":"Development of [89Zr]DFO-Elotuzumab for immunoPET Imaging of CS1 in Multiple Myeloma","volume":"48","author":"Ghai","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2000699","DOI":"10.1080\/2162402X.2021.2000699","article-title":"CS1-Specific Single-Domain Antibodies Labeled with Actinium-225 Prolong Survival and Increase CD8+ T Cells and PD-L1 Expression in Multiple Myeloma","volume":"10","author":"Puttemans","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 Axis in Oncology: The New Kids on the Block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-Specific CAR T Cells Have Potent Activity against Acute Myeloid Leukemia without HSC Toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"56311","DOI":"10.18632\/oncotarget.16910","article-title":"Targeted Alpha Therapy Using a Novel CD70 Targeted Thorium-227 Conjugate in in Vitro and in Vivo Models of Renal Cell Carcinoma","volume":"8","author":"Hagemann","year":"2017","journal-title":"Oncotarget"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/MNM.0000000000000610","article-title":"The Role of 68Ga-DOTA-TATE PET\/CT Scanning in the Evaluation of Patients with Multiple Myeloma: Preliminary Results","volume":"38","author":"Sonmezoglu","year":"2017","journal-title":"Nucl. Med. Commun."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1007\/s00259-021-05433-w","article-title":"PSMA Radioligand Therapy for Solid Tumors Other than Prostate Cancer: Background, Opportunities, Challenges, and First Clinical Reports","volume":"48","author":"Uijen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Miceli, A., Riondato, M., D\u2019Amico, F., Donegani, M.I., Piol, N., Mora, M., Spina, B., Morbelli, S., and Bauckneht, M. (2021). Concomitant Prostate Cancer and Hodgkin Lymphoma: A Differential Diagnosis Guided by a Combined 68Ga-PSMA-11 and 18F-FDG PET\/CT Approach. Medicina, 57.","DOI":"10.3390\/medicina57090975"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/RLU.0000000000001169","article-title":"Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET\/CT","volume":"41","author":"Kanthan","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.21037\/qims-22-1310","article-title":"Multiple Myeloma with Diffuse Uptake on 18F-PSMA-1007 Positron Emission Tomography\/Computed Tomography: A Case Description and Literature Review","volume":"13","author":"Wang","year":"2023","journal-title":"Quant. Imaging Med. Surg."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1355388","DOI":"10.3389\/fimmu.2024.1355388","article-title":"Low-Dose Targeted Radionuclide Therapy Synergizes with CAR T Cells and Enhances Tumor Response","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1247\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:11:27Z","timestamp":1760029887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":136,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17071247"],"URL":"https:\/\/doi.org\/10.3390\/cancers17071247","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]}}}